Radiosensitivity enhancement by dual HER-1/2 inhibitor (GW572016) in SKBR3 human breast carcinoma HER-2+ cell line

Concurrent use of chemotherapy or novel agents in combination with radiation in breast cancer

“…At ASCO 2008, preclinical data were presented on the potential radiotherapy-enhancing effects of the dual HER1/2 tyrosine kinase inhibitor lapatinib in the HER2-overexpressing SKBR3 breast cancer cell line [56]. The half maximal inhibitory concentration (IC 50 ) of lapatinib alone was 50nM, and the IC 50 of radiation alone was 14 Gy.…”